KR20160045728A - 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 - Google Patents
디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 Download PDFInfo
- Publication number
- KR20160045728A KR20160045728A KR1020167004935A KR20167004935A KR20160045728A KR 20160045728 A KR20160045728 A KR 20160045728A KR 1020167004935 A KR1020167004935 A KR 1020167004935A KR 20167004935 A KR20167004935 A KR 20167004935A KR 20160045728 A KR20160045728 A KR 20160045728A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- dimethyl fumarate
- pharmaceutical composition
- administered
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title claims abstract description 158
- 229960004419 dimethyl fumarate Drugs 0.000 title claims abstract description 128
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 70
- 230000003628 erosive effect Effects 0.000 claims abstract description 38
- 239000013563 matrix tablet Substances 0.000 claims abstract description 21
- 239000008203 oral pharmaceutical composition Substances 0.000 claims abstract description 4
- 239000003826 tablet Substances 0.000 claims description 91
- 238000000034 method Methods 0.000 claims description 83
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 67
- 239000000203 mixture Substances 0.000 claims description 66
- 239000008101 lactose Substances 0.000 claims description 62
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 49
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 49
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 47
- 239000004480 active ingredient Substances 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 32
- 239000003607 modifier Substances 0.000 claims description 27
- 238000000576 coating method Methods 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000011230 binding agent Substances 0.000 claims description 20
- 239000002702 enteric coating Substances 0.000 claims description 18
- 238000009505 enteric coating Methods 0.000 claims description 18
- 235000019359 magnesium stearate Nutrition 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 15
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- 229920002678 cellulose Polymers 0.000 claims description 12
- 239000001913 cellulose Substances 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 12
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 11
- 239000000377 silicon dioxide Substances 0.000 claims description 11
- 235000012239 silicon dioxide Nutrition 0.000 claims description 11
- 229920003169 water-soluble polymer Polymers 0.000 claims description 10
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 229920000609 methyl cellulose Polymers 0.000 claims description 6
- 239000001923 methylcellulose Substances 0.000 claims description 6
- 235000010981 methylcellulose Nutrition 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 206010053395 Progressive multiple sclerosis Diseases 0.000 claims description 4
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 5
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 2
- 208000027866 inflammatory disease Diseases 0.000 abstract description 2
- 230000002757 inflammatory effect Effects 0.000 abstract description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 72
- 229960001375 lactose Drugs 0.000 description 58
- 230000002829 reductive effect Effects 0.000 description 28
- 230000000694 effects Effects 0.000 description 24
- 238000009472 formulation Methods 0.000 description 24
- 239000011159 matrix material Substances 0.000 description 24
- 238000012360 testing method Methods 0.000 description 24
- 238000011010 flushing procedure Methods 0.000 description 21
- 239000002245 particle Substances 0.000 description 19
- 230000001276 controlling effect Effects 0.000 description 18
- -1 monomethyl ester Chemical class 0.000 description 18
- 230000002496 gastric effect Effects 0.000 description 17
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 16
- 230000009467 reduction Effects 0.000 description 16
- 201000004681 Psoriasis Diseases 0.000 description 15
- 239000008186 active pharmaceutical agent Substances 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000000227 grinding Methods 0.000 description 13
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 13
- 206010015150 Erythema Diseases 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000000314 lubricant Substances 0.000 description 12
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000001530 fumaric acid Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 10
- 238000007873 sieving Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000654 additive Substances 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 9
- 239000012738 dissolution medium Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 8
- 229920003115 HPC-SL Polymers 0.000 description 7
- 238000007922 dissolution test Methods 0.000 description 7
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 description 7
- 206010000087 Abdominal pain upper Diseases 0.000 description 6
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 6
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 239000007888 film coating Substances 0.000 description 6
- 238000009501 film coating Methods 0.000 description 6
- 210000004211 gastric acid Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 229940005650 monomethyl fumarate Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000004584 weight gain Effects 0.000 description 6
- 235000019786 weight gain Nutrition 0.000 description 6
- 208000004998 Abdominal Pain Diseases 0.000 description 5
- 229910002012 Aerosil® Inorganic materials 0.000 description 5
- 229920003134 Eudragit® polymer Polymers 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000003801 milling Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 238000000859 sublimation Methods 0.000 description 5
- 230000008022 sublimation Effects 0.000 description 5
- 229920003176 water-insoluble polymer Polymers 0.000 description 5
- XLYMOEINVGRTEX-ARJAWSKDSA-N Ethyl hydrogen fumarate Chemical class CCOC(=O)\C=C/C(O)=O XLYMOEINVGRTEX-ARJAWSKDSA-N 0.000 description 4
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 208000004296 neuralgia Diseases 0.000 description 4
- 208000021722 neuropathic pain Diseases 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000001069 triethyl citrate Substances 0.000 description 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 4
- 235000013769 triethyl citrate Nutrition 0.000 description 4
- 208000002881 Colic Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 241000721454 Pemphigus Species 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 3
- XLYMOEINVGRTEX-UHFFFAOYSA-N fumaric acid monoethyl ester Natural products CCOC(=O)C=CC(O)=O XLYMOEINVGRTEX-UHFFFAOYSA-N 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 208000003807 Graves Disease Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000005777 Lupus Nephritis Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 201000009053 Neurodermatitis Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 201000000306 sarcoidosis Diseases 0.000 description 2
- 201000003646 skin sarcoidosis Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 206010011674 Cutaneous sarcoidosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005708 Granuloma Annulare Diseases 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 229920003116 HPC-SSL Polymers 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010059605 Necrobiosis Diseases 0.000 description 1
- 208000015906 Necrobiotic disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- 206010059604 Radicular pain Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920003117 medium viscosity grade hydroxypropyl cellulose Polymers 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020217037254A KR20210139485A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361870096P | 2013-08-26 | 2013-08-26 | |
| US61/870,096 | 2013-08-26 | ||
| EP13181735 | 2013-08-26 | ||
| EP13181735.5 | 2013-08-26 | ||
| US201361895740P | 2013-10-25 | 2013-10-25 | |
| EP13190304 | 2013-10-25 | ||
| EP13190304.9 | 2013-10-25 | ||
| US61/895,740 | 2013-10-25 | ||
| US201462035898P | 2014-08-11 | 2014-08-11 | |
| US62/035,898 | 2014-08-11 | ||
| EP14180569.7 | 2014-08-11 | ||
| EP14180569 | 2014-08-11 | ||
| PCT/EP2014/068094 WO2015028472A1 (en) | 2013-08-26 | 2014-08-26 | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217037254A Division KR20210139485A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160045728A true KR20160045728A (ko) | 2016-04-27 |
Family
ID=52585633
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167004935A Ceased KR20160045728A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
| KR1020217038001A Ceased KR20210147082A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
| KR1020167004936A Ceased KR20160046813A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
| KR1020217037254A Ceased KR20210139485A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217038001A Ceased KR20210147082A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
| KR1020167004936A Ceased KR20160046813A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
| KR1020217037254A Ceased KR20210139485A (ko) | 2013-08-26 | 2014-08-26 | 디메틸푸마레이트를 포함하는 일일 저용량 투여용 약제학적 조성물 |
Country Status (9)
| Country | Link |
|---|---|
| US (11) | US20160206587A1 (enExample) |
| EP (4) | EP3492072A1 (enExample) |
| JP (2) | JP2016531912A (enExample) |
| KR (4) | KR20160045728A (enExample) |
| CN (4) | CN105658207A (enExample) |
| AU (6) | AU2014314230A1 (enExample) |
| CA (2) | CA2918852A1 (enExample) |
| EA (2) | EA201690107A1 (enExample) |
| WO (2) | WO2015028473A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020242132A1 (ko) * | 2019-05-31 | 2020-12-03 | 주식회사 큐라클 | 디메틸푸마르산염을 함유한 장용성 정제 |
| RU2786364C1 (ru) * | 2019-05-31 | 2022-12-20 | Кьюракл Ко., Лтд. | Энтеросолюбильная таблетка, содержащая диметилфумарат |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140640T1 (hr) | 2008-08-19 | 2014-11-21 | Xenoport, Inc. | Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe |
| EP2887935A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| CA2882713A1 (en) | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| TW201516020A (zh) | 2013-09-06 | 2015-05-01 | Xenoport Inc | （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途 |
| IN2013MU03070A (enExample) * | 2013-09-25 | 2015-07-17 | Glenmark Pharmaceuticals Ltd | |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| US10085961B2 (en) | 2015-06-01 | 2018-10-02 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
| WO2017040272A1 (en) * | 2015-08-31 | 2017-03-09 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| WO2017114593A1 (en) * | 2015-12-31 | 2017-07-06 | Zaklady Farmaceutyczne Polpharma S.A. | Process for preparation of an enteric coated granulate comprising dimethyl fumarate |
| KR101800956B1 (ko) * | 2016-04-04 | 2018-01-25 | 주식회사 와이제이테크 | 파이토스핑고신과 효모추출물을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물 |
| RU2616605C1 (ru) * | 2016-04-07 | 2017-04-18 | Олег Ростиславович Михайлов | Кристаллическая бета - модификация (Е)-диметилбутендиоата, способ её получения и фармацевтическая композиция на её основе |
| GR1009149B (el) * | 2016-10-25 | 2017-10-31 | Φαρματεν Αβεε | Φαρμακευτικα σκευασματα που περιλαμβανουν εναν εστερα φουμαρικου οξεως και μεθοδος παραγωγης αυτων |
| WO2020106330A1 (en) * | 2018-07-18 | 2020-05-28 | Pillsy, Inc. | Smart drug delivery and monitoring device, kit, and method of use for pill compounds |
| WO2020053218A1 (en) * | 2018-09-13 | 2020-03-19 | Almirall, S.A. | Treatment of psoriasis |
| TR201818859A2 (tr) * | 2018-12-07 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat ve en az bi̇r kas gevşeti̇ci̇ ajan i̇çeren bi̇r kombi̇nasyon |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| AU2021210629A1 (en) * | 2020-05-06 | 2022-12-08 | Imcyse Sa | Peptides and methods for the treatment of multiple sclerosis |
| WO2022212893A1 (en) * | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| CN115707456A (zh) * | 2021-08-19 | 2023-02-21 | 成都百裕制药股份有限公司 | 一种富马酸二甲酯肠溶微片及其制备方法 |
| US20230083647A1 (en) * | 2021-09-10 | 2023-03-16 | Battelle Energy Alliance, Llc | Reusable structures containing isotopes for simulating radioactive contamination environments, and methods of formation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| PL2316430T3 (pl) | 2004-10-08 | 2012-11-30 | Forward Pharma As | Kompozycje farmaceutyczne o kontrolowanym uwalnianiu, zawierające ester kwasu fumarowego |
| CN101304732A (zh) * | 2005-10-07 | 2008-11-12 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| WO2007042034A1 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| WO2010079222A1 (en) * | 2009-01-09 | 2010-07-15 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| EP2379062A1 (en) * | 2009-01-09 | 2011-10-26 | Forward Pharma A/S | Pharmaceutical composition comprising one or more fumaric acid esters |
-
2014
- 2014-08-26 WO PCT/EP2014/068095 patent/WO2015028473A1/en not_active Ceased
- 2014-08-26 KR KR1020167004935A patent/KR20160045728A/ko not_active Ceased
- 2014-08-26 CN CN201480047436.4A patent/CN105658207A/zh active Pending
- 2014-08-26 EA EA201690107A patent/EA201690107A1/ru unknown
- 2014-08-26 CN CN201811202821.8A patent/CN109453133A/zh active Pending
- 2014-08-26 EP EP18198841.1A patent/EP3492072A1/en not_active Withdrawn
- 2014-08-26 KR KR1020217038001A patent/KR20210147082A/ko not_active Ceased
- 2014-08-26 EP EP18198844.5A patent/EP3517102A1/en not_active Withdrawn
- 2014-08-26 JP JP2016537270A patent/JP2016531912A/ja active Pending
- 2014-08-26 US US14/914,031 patent/US20160206587A1/en not_active Abandoned
- 2014-08-26 US US14/914,025 patent/US20160206586A1/en not_active Abandoned
- 2014-08-26 EP EP14755672.4A patent/EP3038605A1/en not_active Withdrawn
- 2014-08-26 CN CN201480047438.3A patent/CN105682648A/zh active Pending
- 2014-08-26 CA CA2918852A patent/CA2918852A1/en not_active Abandoned
- 2014-08-26 KR KR1020167004936A patent/KR20160046813A/ko not_active Ceased
- 2014-08-26 EP EP14755818.3A patent/EP3038606A1/en not_active Withdrawn
- 2014-08-26 EA EA201690102A patent/EA201690102A1/ru unknown
- 2014-08-26 KR KR1020217037254A patent/KR20210139485A/ko not_active Ceased
- 2014-08-26 CN CN201811067557.1A patent/CN109223725A/zh active Pending
- 2014-08-26 CA CA2918846A patent/CA2918846A1/en not_active Abandoned
- 2014-08-26 AU AU2014314230A patent/AU2014314230A1/en not_active Abandoned
- 2014-08-26 WO PCT/EP2014/068094 patent/WO2015028472A1/en not_active Ceased
- 2014-08-26 JP JP2016537269A patent/JP2016528302A/ja active Pending
- 2014-08-26 AU AU2014314231A patent/AU2014314231A1/en not_active Abandoned
-
2017
- 2017-05-02 US US15/584,439 patent/US20170231943A1/en not_active Abandoned
- 2017-10-03 US US15/723,749 patent/US20180021289A1/en not_active Abandoned
- 2017-12-07 US US15/834,799 patent/US20180092875A1/en not_active Abandoned
-
2018
- 2018-05-15 US US15/979,894 patent/US20180256530A1/en not_active Abandoned
- 2018-07-26 US US16/046,028 patent/US20180338946A1/en not_active Abandoned
- 2018-12-20 US US16/227,089 patent/US20190125711A1/en not_active Abandoned
-
2019
- 2019-03-06 US US16/294,515 patent/US20190201369A1/en not_active Abandoned
- 2019-11-18 AU AU2019268052A patent/AU2019268052B2/en not_active Ceased
- 2019-11-18 AU AU2019268049A patent/AU2019268049B2/en not_active Ceased
-
2020
- 2020-10-26 US US17/080,570 patent/US20210290582A1/en not_active Abandoned
-
2021
- 2021-08-13 AU AU2021215272A patent/AU2021215272A1/en not_active Abandoned
- 2021-11-19 AU AU2021269434A patent/AU2021269434A1/en not_active Abandoned
-
2022
- 2022-02-16 US US17/673,708 patent/US20220168255A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020242132A1 (ko) * | 2019-05-31 | 2020-12-03 | 주식회사 큐라클 | 디메틸푸마르산염을 함유한 장용성 정제 |
| RU2786364C1 (ru) * | 2019-05-31 | 2022-12-20 | Кьюракл Ко., Лтд. | Энтеросолюбильная таблетка, содержащая диметилфумарат |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019268049B2 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| JP5788331B2 (ja) | 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤 | |
| JP7195354B2 (ja) | 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤 | |
| JP2021181483A (ja) | 低１日用量で投与するためのフマル酸ジメチルを含む医薬組成物 | |
| HK40012188A (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| HK40009517A (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
| EA042106B1 (ru) | Фармацевтический состав, содержащий один или более эфиров фумаровой кислоты в разлагаемой матрице |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160224 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 20180918 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190823 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20201021 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210813 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20201021 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20211115 |